NewAmsterdam Pharma begins Phase 2b trial of obicetrapib in Alzheimer's

September 29, 2026 8:00 AM

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announced the dosing of the first participant in SPINOZA, a Phase 2b clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found